Dr. Sohi on the future of PSMA-PET imaging in prostate cancer
EP: 1.Harnessing the Full Power of PSMA-PET Requires Multidisciplinary Approach
EP: 2.Dr. Spratt on the importance of a multidisciplinary approach to PSMA-PET
EP: 3.PSMA-PET leads imaging breakthroughs in prostate cancer paradigm
EP: 4.Conventional imaging obstacles that PSMA-PET overcomes
EP: 5.Dr. Sohi on the timing of PSMA-PET imaging in prostate cancer
EP: 6.Dr. Sohi on why PSMA-PET results can alter treatment plans
EP: 7.Dr. Sohi on the future of PSMA-PET imaging in prostate cancer
In this video, Jaideep S. Sohi, MD, shares his vision for the future of PSMA-PET imaging in prostate cancer. Sohi is a nuclear medicine physician with Northwestern University and American Molecular Imaging.
Transcription
PSMA-PET has only been around for about 3 years, give or take, and you can see it's already made a tremendous impact in utilization and impacting patient care. It has facilitated more accurate staging and restaging of these patients with prostate carcinoma. I think the utilization of this modality, this tracer, will only increase when we look down the road 5 to 10 years from now. I think it is feasible to see PSMA-PET being used at an even earlier time point, which would mean using this imaging modality in conjunction with MRI to evaluate patients with signs and symptoms that are concerning for potential prostate carcinoma (rising or abnormal PSA levels) to basically help diagnose the patient. And there might even be the potential that one day PSMA-PET imaging could actually replace MRI, but that is yet to be determined.
Transcription has been edited for clarity.
